viral therapy in treating patients with recurrent glioblastoma multiforme

Conditions: Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Mixed Glioma; Recurrent Glioblastoma

Summary: this phase i trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (mv-cea) in treating patients with glioblastoma multiforme that has come back. a virus, called mv-cea, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

primary objectives: i. to assess the safety and toxicity of intratumoral and resection cavity administration of an edmonston's strain measles virus genetically engineered to produce cea (mv-cea) in patients with recurrent glioblastoma multiforme. ii. to determine the maximum tolerated dose (mtd) of mv-cea. iii. to characterize viral gene expression at each dose level as manifested by cea titers. iv. to assess viremia, viral replication, and measles virus shedding/persistence following intratumoral administration. v. to assess humoral and cellular immune response to the injected virus. vi. to assess in a preliminary fashion antitumor efficacy of this approach. outline: this is a dose-escalation study. patients are assigned to 1 of 2 sequential treatment arms. arm a (resection cavity administration): patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by mv-cea administered into the resection cavity. arm b (intratumoral and resection cavity administration): patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by carcinoembryonic antigen-expressing measles virus intratumorally (it) through the catheter over 10 minutes on day 1. patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by mv-cea administered around the tumor bed. after completion of study treatment, patients are followed up at 28 days (non-cohort i patients), 7 weeks (patients in cohort i only), every 2 months until progression, every 3 and 12 months after progression, and then yearly thereafter for up to 15 years.

Eligibility criteria:
inclusion criteria: * recurrent grade 3 or 4 glioma, including astrocytoma, oligodendroglioma or mixed glioma with histologic confirmation at initial diagnosis or recurrence * candidate for gross total or subtotal resection * absolute neutrophil count (anc) \>= 1500/ul * platelets (plt) \>= 100,000/ul * total bilirubin =\< 1.5 x upper normal limit (uln) * aspartate aminotransferase (ast) =\< 2 x uln * creatinine =\< 2.0 x uln * hemoglobin (hgb) \>= 9.0 gm/dl * prothrombin time (pt) and activated partial thromboplastin time (aptt) =\< 1.3 x uln * ability to provide informed consent * eastern cooperative oncology group (ecog) performance status (ps) 0, 1 or 2 * anti-measles virus immunity as demonstrated by immunoglobulin g (igg) anti-measles antibody levels of \>= 1.1 eu/ml as determined by enzyme immunoassay * normal serum cea levels (\< 3 ng/ml) at the time of registration * willing to provide biologic specimens as required by the protocol * negative serum pregnancy test done =\< 7 days prior to registration (for women of childbearing potential only) exclusion criteria: * any of the following: * pregnant women * nursing women * men or women of childbearing potential who are unwilling to employ adequate contraception * active infection =\< 5 days prior to registration * history of tuberculosis or history of purified protein derivative (ppd) positivity * any of the following therapies: * chemotherapy =\< 4 weeks prior to registration (6 wks for nitrosourea-based chemotherapy) * immunotherapy =\< 4 weeks prior to registration * biologic therapy =\< 4 weeks prior to registration * bevacizumab =\< 12 weeks prior to registration * non-cytotoxic antitumor drugs, i.e., small molecule cell cycle inhibitors =\< 2 weeks prior to registration * radiation therapy =\< 6 weeks prior to registration * any viral or gene therapy prior to registration * failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment * new york heart association classification iii or iv * requiring blood product support * inadequate seizure control * expected communication between ventricles and resection cavity as a result of surgery * human immunodeficiency virus (hiv)-positive test result, or history of other immunodeficiency * history of organ transplantation * history of chronic hepatitis b or c * other concurrent chemotherapy, immunotherapy, radiotherapy or any ancillary therapy considered investigational (utilized for a non-food and drug administration \[fda\]-approved indication and in the context of a research investigation) * exposure to household contacts =\< 15 months old or household contact with known immunodeficiency * allergy to measles vaccine or history of severe reaction to prior measles vaccination